Back

Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity

30 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Drug interactions, efficacy, and safety Cardiotoxicity of Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Jong-Hwan Joseph Lee

Toronto (Canada)

7 More presentations in this session

Presentation thumbnail
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
Ms A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device
Doctor K. Murata (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Drug-drug interactions of empagliflozin and dapagliflozin
Professor C. Stoellberger (Wien, AT)
Abstract Slides Video
Presentation thumbnail
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study
Mr S. Nielsen (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Drug interactions, efficacy, and safety

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study
thumbnail
Congress Presentation
Deciphering doxorubicin-induced cardiotoxicity:insights at single-cell resolution
thumbnail
Congress Presentation
New strategies to protect against anthracycline cardiotoxicity

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources